For Investors

Strandwise is an oncology-focused biotechnology company developing a new class of autonomous scientific infrastructure to accelerate cancer detection and therapeutic discovery.

We integrate advanced diagnostics, mechanism-driven therapeutics, and continuous AI-guided research into a single, defensible platform.

Our goal is not incremental improvement—but structural acceleration of oncology R&D.  

Cancer research is not constrained by data.
It is constrained by human synthesis capacity.

• Millions of biomedical papers published each year
   
• Fragmented experimental evidence across institutions
   
• High attrition in oncology drug development
   
• Late detection remains a leading driver of mortality
   

Strandwise addresses this gap by building systems that continuously reason across global oncology knowledge, rather than relying on static datasets or episodic discovery cycles.

Aetherion is our continuously operating scientific engine that:

• Monitors trusted biomedical sources, including the National Library of Medicine
   
• Structures and prioritizes oncology research insights
   
• Guides diagnostic and therapeutic hypothesis generation
   
• Evolves its reasoning as new evidence emerges
   

This enables Strandwise to operate with compounding discovery velocity.

Strandwise is developing both diagnostics and therapeutics within a single platform, creating a powerful feedback loop.

Diagnostics — Skopeion™ Biosensor

• Next-generation biosensor chip for detecting free cancer cells and tumor-associated biological signatures
   
• Built with advanced nanotechnology
   
• Designed for early detection, monitoring, and treatment response assessment
   

• Two molecular programs in development
   
• Initial focus on:
   
  • Pancreatic cancer
     
  • Colorectal cancer
     
  • Gastric cancer
     

These indications were selected for their high unmet need, poor prognosis, and clear translational pathways.

Most biotech pipelines are built on frozen assumptions.
Ours updates continuously as oncology research evolves.

Insights from diagnostics inform therapeutic discovery—and vice versa—reducing downstream risk and increasing translational clarity.

Strandwise is built on proprietary computational and data infrastructure designed specifically for biological systems, creating a durable moat beyond any single asset.

We prioritize depth over breadth, starting with gastrointestinal oncology where impact and value creation are clearest.

• Oncology is a multi-hundred-billion-dollar global market
   
• Early detection and precision therapeutics represent some of the fastest-growing segments
   
• Pancreatic, colorectal, and gastric cancers remain areas of high unmet need
   

Strandwise is positioned to generate value through:

• Platform licensing
   
• Diagnostic partnerships
   
• Therapeutic development and partnering
   
• Long-term pipeline expansion
   

Investment supports:

• Advancement of the Skopeion biosensor platform
   
• Progression of two gastrointestinal oncology therapeutic programs
   
• Expansion of Aetherion’s autonomous discovery capabilities
   
• Strategic partnerships and translational validation
   

Our model is designed to create multiple value inflection points, not a single binary outcome.

We believe the future of oncology will be shaped by systems that can reason continuously, integrate evidence transparently, and accelerate discovery responsibly.

Strandwise is building that future.